利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

36 条记录 (耗时 0.016 秒)

    MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS
    2.
    发明申请
    MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS 有权

    公开(公告)号：US20210178050A1

    公开(公告)日：2021-06-17

    申请号：US17119423

    申请日：2020-12-11

    申请人： EpicentRx, Inc.

    发明人： Bryan T. Oronsky ,  Scott Caroen

    IPC分类号： A61M1/36 ,  A61M1/38

    摘要： Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

    IMMUNOMODULATORY FUSION PROTEINS
    4.
    发明申请
    IMMUNOMODULATORY FUSION PROTEINS 审中-公开

    公开(公告)号：US20200223901A1

    公开(公告)日：2020-07-16

    申请号：US16651079

    申请日：2018-09-27

    申请人： EpicentRx, Inc.

    发明人： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

    IPC分类号： C07K14/715 ,  C07K14/54 ,  C12N15/62 ,  A61P35/00

    摘要： Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

    ANTI-ANGIOGENIC ADENOVIRUS
    9.
    发明申请
    ANTI-ANGIOGENIC ADENOVIRUS 审中-公开

    公开(公告)号：US20200155625A1

    公开(公告)日：2020-05-21

    申请号：US16616146

    申请日：2018-05-24

    申请人： EpicentRx, Inc.

    发明人： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

    IPC分类号： A61K35/761 ,  C12N7/00 ,  C12N15/86 ,  A61K39/395 ,  A61P35/00

    摘要： The invention relates to a recombinant adenovirus that expresses endostatin, angiostatin, or a combination of endostatin and angiostatin. The invention also relates to method of treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of a combination of (i) a recombinant adenovirus and (ii) an anti-angiogenic agent to treat the cancer in the subject.

    TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS
    10.
    发明申请
    TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS 审中-公开

    公开(公告)号：US20190352669A1

    公开(公告)日：2019-11-21

    申请号：US16482049

    申请日：2018-01-30

    申请人： EpicentRx, Inc.

    发明人： Tony R. Reid ,  Bryan T. Oronsky ,  Farah Hedjran ,  Christopher Larson

    IPC分类号： C12N15/86 ,  A61K35/761

    摘要： The invention provides, e.g., a recombinant virus comprising (i) a modified TATA box-based promoter, and/or (ii) a modified CAAT box-based promoter operably linked to a gene, wherein the modified TATA box-based promoter and/or modified CAAT box-based promoter lacks a functional TATA box and/or CAAT box and permit selective expression of the gene in a hyperproliferative cell. The recombinant viruses can be used to treat cell proliferative diseases and disorders, including certain forms of cancer.